No annual revenue total was found in ANEBULO PHARMACEUTICALS, INC.'s SEC filings.
Anebulo Pharmaceuticals, Inc. (ANEB) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue
—
Net income (TTM)
$-7.98M
-4.1% vs year-ago TTM
Operating cash flow (TTM)
$-5.84M
+12.1% vs year-ago TTM
Free cash flow
—
EPS (TTM)
$-0.19
+33.3% vs year-ago TTM
Dividend per share
None
Shares outstanding
41.08M
+58.4% vs prior year
Net cash
—
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ANEB (OTC)
- Fiscal year ends
- June 30
- Incorporated in
- DE
- Headquarters
- Lakeway, TX
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1815974
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Jun 30, 2025 |
FY 2024 Jun 30, 2024 |
FY 2023 Jun 30, 2023 |
FY 2022 Jun 30, 2022 |
FY 2021 Jun 30, 2021 |
|---|---|---|---|---|---|
| Operating income | -$9.2M | -$8.3M | -$11.8M | -$6.8M | — |
| Net income | -$8.5M | -$8.2M | -$11.7M | -$6.8M | -$30.3M |
| Diluted EPS | -$0.25 | -$0.32 | -$0.47 | — | — |
| Operating cash flow | -$6.3M | -$8.1M | -$9.7M | -$5.4M | -$4.9M |
| Total assets | $12.1M | $4.1M | $11.7M | $15.6M | $21.7M |
| Total liabilities | $487,688 | $260,583 | $1.1M | $512,531 | $241,633 |
| Stockholders' equity | $11.7M | $3.8M | $10.6M | $15.1M | $21.4M |
| Cash and investments | $11.6M | $3.1M | $11.2M | $14.5M | $20.0M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Feb 12, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Results of operations
|
Feb 12, 2026 | Feb 12, 2026 |
| 8-K |
Current report
Listing notice, Other events
|
Feb 6, 2026 | Feb 5, 2026 |
| 8-K |
Current report
Other events
|
Jan 29, 2026 | Jan 29, 2026 |
| 8-K |
Current report
Other events
|
Jan 27, 2026 | Jan 26, 2026 |
| 8-K |
Current report
Other events
|
Dec 22, 2025 | Dec 22, 2025 |
All 204 Anebulo Pharmaceuticals, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.